VANGUARD GROUP INC 13D and 13G filings for TG Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-08 11:29 am Purchase |
2024-12-31 | 13G | TG Therapeutics, Inc. TGTX |
VANGUARD GROUP INC | 15,596,480 10.010% |
1,925,536 (+14.08%) |
Filing |
| 2024-02-13 5:15 pm Sale |
2023-12-29 | 13G | TG Therapeutics, Inc. TGTX |
VANGUARD GROUP INC | 13,670,944 9.030% |
-1,831,820 (-11.82%) |
Filing |
| 2023-02-09 11:35 am Purchase |
2022-12-30 | 13G | TG Therapeutics, Inc. TGTX |
VANGUARD GROUP INC | 15,502,764 10.670% |
756,372 (+5.13%) |
Filing |
| 2022-10-11 10:07 am Purchase |
2022-09-30 | 13G | TG Therapeutics, Inc. TGTX |
VANGUARD GROUP INC | 14,746,392 10.150% |
2,654,955 (+21.96%) |
Filing |
| 2022-02-10 08:42 am Purchase |
2021-12-31 | 13G | TG Therapeutics, Inc. TGTX |
VANGUARD GROUP INC | 12,091,437 8.460% |
1,120,574 (+10.21%) |
Filing |
| 2021-02-10 11:57 am Purchase |
2020-12-31 | 13G | TG Therapeutics, Inc. TGTX |
VANGUARD GROUP INC | 10,970,863 8.110% |
10,970,863 (New Position) |
Filing |